CG
ABCL icon

Cutler Group’s AbCellera Biologics ABCL Stock Holding History

Cutler Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,400
Closed -$95K – 3670
2022
Q4 		$95K Buy
9,400
+2,654
+39% +$30.7K 0.01% 1180
2022
Q3 		$66K Buy
+6,746
New +$74K 0.01% 1692
2022
Q2 		– Sell
-2,200
Closed -$18.6K – 4867
2022
Q1 		$21K Sell
2,200
-3,191
-59% -$30.2K ﹤0.01% 2994
2021
Q4 		$77K Buy
5,391
+4,601
+582% +$69.8K 0.01% 2047
2021
Q3 		$15K Sell
790
-2,810
-78% -$49.7K ﹤0.01% 3570
2021
Q2 		$79K Buy
3,600
+2,200
+157% +$60.7K 0.01% 2070
2021
Q1 		$47K Buy
+1,400
New +$55.8K ﹤0.01% 2449

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return